checkAd

     1734  0 Kommentare Retina Implant AG and Okuvision to Present Patient Perspectives and Clinical Data at the Retina International World Congress 2016 - Seite 2


    Speaking of the upcoming presentations, Reinhard Rubow, Board Member of Retina Implant AG said, "We are extremely excited to be presenting at the RIWC this week and are delighted that Mr. Böhm will be attending, giving us an unparalleled opportunity to understand the patient perspective from a current user of our device. We are also very excited to be presenting the results of our OkuStim trial data, which is a new therapy for early and intermediate stage RP patients."

    About Retina Implant AG 

    Retina Implant AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals and institutes which began with a large grant from the German Federal Ministry of Research and Education in 1996, Retina Implant AG was founded by Dr. Eberhart Zrenner, professor of Ophthalmology, University of Tübingen, Germany and his colleagues in 2003 with private investors with the goal of developing a fully-functioning electronic retinal implant to restore useful vision to the blind. Retina Implant began implanting human patients in 2005 and started a second, larger clinical trial in 2010. In July 2013, Retina Implant's wireless subretinal implant technology, Alpha IMS, received CE mark. The Alpha AMS subretinal implant was CE-marked in March 2016. To learn more, visit http://www.retina-implant.de/.

    About Okuvision GmbH 

    Founded by the leaders of Retina Implant AG in 2007, Okuvision GmbH is an innovator in the field of transcorneal electrical stimulation (TES) therapy for patients with early and intermediate stage of retinitis pigmentosa (RP). Building on the lessons learned through the use of Retina Implant's subretinal implant technology, Okuvision was founded with the goal to develop a treatment for RP. In December 2011 OkuStim® received CE mark approval for use as a treatment to help delay the progression of RP. To learn more, please visit: http://www.okuvision.de.    

    For more information please visit Retina Implant & Okuvision at their booth on site at the RIWC exhibition (-South Foyer B1+2).


    MSLGROUP:
    Sarah Herbert                 
    +44(0)20-3219-8708               
    RetinaImplant@mslgroup.com


    Retina Implant AG:
    Reinhard Rubow
    +49-7121-36403-100
    Reinhard.Rubow@Retina-Implant.de

    Seite 2 von 2



    PR Newswire (engl.)
    0 Follower
    Autor folgen
    Verfasst von PR Newswire (engl.)
    Retina Implant AG and Okuvision to Present Patient Perspectives and Clinical Data at the Retina International World Congress 2016 - Seite 2 TAIPEI, Taiwan, July 9, 2016 /PRNewswire/ - Retina Implant will be presenting the scientific rationale as well as having a patient offering their perspective of the device in practice.   Retina Implant AG, the leading developer of subretinal …